Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions
Provided By PR Newswire
Last update: Jun 12, 2025
SINGAPORE, June 12, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the expansion of its existing supply and distribution agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), to launch and distribute two additional medicines from its oncology portfolio in Australia, New Zealand and Singapore, with an option to add further countries in the Asia-Pacific region. The expanded agreement will see new therapies axatilimab (registered as Niktimvo® in the United States) and retifanlimab (registered as Zynyz® in the U.S. and European Union) added to the current partnered portfolio of Minjuvi® (tafasitamab) and Pemazyre® (pemigatinib).
Read more at prnewswire.com68.27
-0.54 (-0.78%)
Find more stocks in the Stock Screener
INCY Latest News and Analysis
3 days ago - ChartmillStay updated with the S&P500 stocks that are on the move in today's pre-market session.The US market session of Monday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today.
20 days ago - ChartmillINCYTE CORP (NASDAQ:INCY) – A Potential Undervalued Opportunity in BiotechINCYTE CORP (NASDAQ:INCY) presents a compelling value case with strong profitability, low debt, and an attractive valuation. The biotech firm's fundamentals suggest potential upside for long-term investors.
